Article
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
Nature - 28 Jun 2012
Diaz Luis A, Williams Richard T, Wu Jian, Kinde Isaac, Hecht J Randolph, Berlin Jordan, Allen Benjamin, Bozic Ivana, Reiter Johannes G, Nowak Martin A, Kinzler Kenneth W, Oliner Kelly S, Vogelstein Bert
Abstract excerpt
Colorectal tumours that are wild type for KRAS are often sensitive to EGFR blockade, but almost always develop resistance within several months of initiating therapy. The mechanisms underlying this acquired resistance to anti-EGFR antibodies are largely unknown. This situation is in marked contrast to that of small-molecule targeted agents, such as inhibitors of ABL, EGFR, BRAF and MEK, in which mutations in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.